Nebivolol - NDSRI's
References
FAQ's
References
- Trinka, Peter; Reiter, Jozsef; Berecz, Gabor; Simig, Gyula, New Process For The Preparation Of Racemic ([2S[2R*[R[R*]]]] And ([2R[2S*[S[S*]]]]-(±)- Α,Α' -[Imino-Bis(Methylene)]Bis[6-Fluorochroman-2-Methanol] AND ITS PURE [2S[2R*[R[R*]&, Egis Gyogyszergyar Rt., Hungary, WO2004041805A1, May 21, 2004
- Ramakrishna, N. V. S.; Vishwottam, K. N.; Koteshwara, M.; Manoj, S.; Santosh, M.; Varma, D. P., Rapid quantification of Nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, Volume: 39, Issue: 5, Pages: 1006-1013, 2005
Frequently Asked Questions
How are Nebivolol impurities detected and quantified?
Analytical Methods like reverse-phase ultra-performance liquid chromatographic method help estimate Nebivolol impurities quantitatively.
Can Nebivolol impurities affect patient safety?
Yes, impurities in Nebivolol can impact patient safety. Depending on their nature and concentration, contaminants can cause adverse effects or reduce the efficacy of the medication.
Which solvents help in the analysis of Nebivolol impurities?
Methanol is employed to attain the ideal solubility and differentiation of impurities in Nebivolol.
What are the temperature conditions required to store Nebivolol impurities?
Nebivolol impurities should generally be stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.